Zobrazeno 1 - 10
of 14
pro vyhledávání: '"T. W. Malpass"'
Autor:
Dennie V. Jones, Martin J. Edelman, T. W. Malpass, Tarak D. Mody, Gregory A. Otterson, Joseph W. Leach, Ravi Salgia, Ramaswamy Govindan
Publikováno v:
Journal of Thoracic Oncology. 6:786-789
Background: Motexafin gadolinium (MGd) disrupts redox-dependent pathways by inhibiting oxidative stress-related proteins leading to apoptosis. MGd selectively targets tumor cells, disrupting energy metabolism and repair mechanisms, rendering cells mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572f5c2742d86dcbd4a9e59ca9cbd71f
https://doi.org/10.1097/jto.0b013e31820a443f
https://doi.org/10.1097/jto.0b013e31820a443f
Autor:
Pamela J. Paley, Kathryn F. McGonigle, Jacqueline Vuky, Benjamin E. Greer, Barbara A. Goff, Howard G. Muntz, Dan S. Veljovich, T. W. Malpass, Heidi J. Gray
Publikováno v:
Cancer. 117:3731-3740
BACKGROUND: A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC). METHOD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b6c255d4e6c202d54bc356d816c7b9
https://doi.org/10.1002/cncr.25967
https://doi.org/10.1002/cncr.25967
Publikováno v:
Cancer. 113(3)
BACKGROUND. Intravenous topotecan is approved for the treatment of ovarian cancer (OC). In intraperitoneal (i.p.) topotecan studies, 20 mg/m2 dosing was tolerable. This study evaluated the feasibility, safety, and preliminary efficacy of i.p. topotec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f547f8857b2b55900f936540d2280ba
https://pubmed.ncbi.nlm.nih.gov/18521923
https://pubmed.ncbi.nlm.nih.gov/18521923
Publikováno v:
Journal of Clinical Oncology. 27:4606-4606
4606 Background: Metastatic pancreas cancer (MPC) remains identified with poor outcome. Benchmark response statistics in MPC include response rate (RR) 20–30%, time to disease progression (TTP) 3.5–5.5 mo, median overall survival (OS) 6–9 mo an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff2b1b44ed2a032cb137a87506d8b83
https://doi.org/10.1200/jco.2009.27.15_suppl.4606
https://doi.org/10.1200/jco.2009.27.15_suppl.4606
Autor:
T. W. Malpass, D. S. Veljovich, Heidi J. Gray, J. L. Vuky, Kathryn F. McGonigle, Howard G. Muntz, Pamela J. Paley
Publikováno v:
Journal of Clinical Oncology. 26:5551-5551
5551 Background: Patients (pts) with platinum refractory OC have limited treatment options. Bevacizumab, an anti- angiogenesis agent has demonstrated efficacy in recurrent ovarian cancer. Bevacizum...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09bb833947e358f05bef8e50b7b665f6
https://doi.org/10.1200/jco.2008.26.15_suppl.5551
https://doi.org/10.1200/jco.2008.26.15_suppl.5551
Publikováno v:
Journal of Clinical Oncology. 25:5570-5570
5570 Background: Previous studies with intraperitoneal (IP) topotecan have shown 20 mg/m2 to be well tolerated. This study evaluated the feasibility, safety, and effectiveness of IP topotecan as consolidation therapy for ovarian cancer. Methods: Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3da8902c2c16790c7ed30c3a51c646ac
https://doi.org/10.1200/jco.2007.25.18_suppl.5570
https://doi.org/10.1200/jco.2007.25.18_suppl.5570
Publikováno v:
Journal of Clinical Oncology. 22:5077-5077
5077 Background: Intravenous (IV) topotecan is approved for the treatment of ovarian cancer. Previous studies with intraperitoneal topotecan have shown 20 mg/m2 to be well tolerated. This is an int...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb59cb259b6364343a30b449164e0081
https://doi.org/10.1200/jco.2004.22.90140.5077
https://doi.org/10.1200/jco.2004.22.90140.5077
Publikováno v:
Blood. 64:458-469
Platelet-derived growth factor (PDGF) is a potent mitogen for many cultured connective tissue cells. It is present in concentrated form within the platelet alpha-granules and is believed to be released during platelet degranulation at sites of vascul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe602939dbe7c17971a6a2b5f9d5b8cc
https://doi.org/10.1182/blood.v64.2.458.458
https://doi.org/10.1182/blood.v64.2.458.458
Publikováno v:
The Journal of laboratory and clinical medicine. 103(6)
Nine patients with myelodysplasia or myeloproliferative syndrome were studied with respect to platelet count and volume, 51Cr and 14C-serotonin platelet kinetics, bleeding time, and platelet dense and alpha-granule contents. Platelet counts ranged fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::37ac98aeef72ec3b9147d83016b15fb3
https://pubmed.ncbi.nlm.nih.gov/6233383
https://pubmed.ncbi.nlm.nih.gov/6233383
Autor:
T W, Malpass, L A, Harker
Publikováno v:
Seminars in hematology. 17(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cefde8d619d54379352ca130f6cc8eee
https://pubmed.ncbi.nlm.nih.gov/7003720
https://pubmed.ncbi.nlm.nih.gov/7003720